was read the article
array:23 [ "pii" => "S2530016419302071" "issn" => "25300164" "doi" => "10.1016/j.endinu.2019.07.012" "estado" => "S300" "fechaPublicacion" => "2020-02-01" "aid" => "971" "copyright" => "SEEN y SED" "copyrightAnyo" => "2019" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Endocrinol Diabetes Nutr. 2020;67:137-47" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 181 "formatos" => array:2 [ "HTML" => 94 "PDF" => 87 ] ] "itemSiguiente" => array:18 [ "pii" => "S2530016419301752" "issn" => "25300164" "doi" => "10.1016/j.endinu.2019.06.006" "estado" => "S300" "fechaPublicacion" => "2020-02-01" "aid" => "956" "copyright" => "SEEN y SED" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Endocrinol Diabetes Nutr. 2020;67:148-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 22 "formatos" => array:2 [ "HTML" => 16 "PDF" => 6 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>" "titulo" => "Carglumic acid (Carbaglu®) treatment in hyperammonemia post liver transplantation" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "148" "paginaFinal" => "149" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tratamiento con ácido carglúmico (Carbaglu®) en la hiperamoniemia post transplante hepático" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 828 "Ancho" => 1520 "Tamanyo" => 88904 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Urea cycle.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Francisco Arrieta, Amaya Belanger-Quintana, Luis Gajate, Javier Grau, Rosario Pintor" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Francisco" "apellidos" => "Arrieta" ] 1 => array:2 [ "nombre" => "Amaya" "apellidos" => "Belanger-Quintana" ] 2 => array:2 [ "nombre" => "Luis" "apellidos" => "Gajate" ] 3 => array:2 [ "nombre" => "Javier" "apellidos" => "Grau" ] 4 => array:2 [ "nombre" => "Rosario" "apellidos" => "Pintor" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016419301752?idApp=UINPBA00004N" "url" => "/25300164/0000006700000002/v1_202002131357/S2530016419301752/v1_202002131357/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2530016419301077" "issn" => "25300164" "doi" => "10.1016/j.endinu.2019.03.011" "estado" => "S300" "fechaPublicacion" => "2020-02-01" "aid" => "919" "copyright" => "SEEN y SED" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Endocrinol Diabetes Nutr. 2020;67:130-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 157 "formatos" => array:2 [ "HTML" => 110 "PDF" => 47 ] ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">ORIGINAL</span>" "titulo" => "Rendimiento diagnóstico del sistema de evaluación de riesgo ecográfico del nódulo tiroideo de la American Thyroid Association en endocrinología (estudio ETIEN 3)" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "130" "paginaFinal" => "136" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Diagnostic performance of the American Thyroid Association ultrasound risk assessment of thyroid nodules in endocrinology (the ETIEN 3 study)" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Florentino Carral, María del Carmen Ayala, Ana Isabel Jiménez, Concepción García, María Isabel Robles, Eulalia Porras, Vicente Vega" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Florentino" "apellidos" => "Carral" ] 1 => array:2 [ "nombre" => "María del Carmen" "apellidos" => "Ayala" ] 2 => array:2 [ "nombre" => "Ana Isabel" "apellidos" => "Jiménez" ] 3 => array:2 [ "nombre" => "Concepción" "apellidos" => "García" ] 4 => array:2 [ "nombre" => "María Isabel" "apellidos" => "Robles" ] 5 => array:2 [ "nombre" => "Eulalia" "apellidos" => "Porras" ] 6 => array:2 [ "nombre" => "Vicente" "apellidos" => "Vega" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2530018020300160" "doi" => "10.1016/j.endien.2019.03.015" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530018020300160?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016419301077?idApp=UINPBA00004N" "url" => "/25300164/0000006700000002/v1_202002131357/S2530016419301077/v1_202002131357/es/main.assets" ] "en" => array:19 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "Maturity-onset diabetes of the young: From a molecular basis perspective toward the clinical phenotype and proper management" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "137" "paginaFinal" => "147" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Sofia Castro Oliveira, João Sérgio Neves, Antonio Pérez, Davide Carvalho" "autores" => array:4 [ 0 => array:4 [ "nombre" => "Sofia Castro" "apellidos" => "Oliveira" "email" => array:1 [ 0 => "sofiacastro.oliveira@gmail.com" ] "referencia" => array:4 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] 3 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "João Sérgio" "apellidos" => "Neves" "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] ] 2 => array:3 [ "nombre" => "Antonio" "apellidos" => "Pérez" "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 3 => array:3 [ "nombre" => "Davide" "apellidos" => "Carvalho" "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] ] ] "afiliaciones" => array:6 [ 0 => array:3 [ "entidad" => "Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, Porto, Portugal" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Faculty of Medicine of the Universidade do Porto, Porto, Portugal" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Department of Endocrinology and Nutrition, Hospital Santa Creu i Sant Pau, Barcelona, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "CIBER de Diabetes y Enfermidades Metabólicas Asociadas (CIBERDEM), Madrid, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal" "etiqueta" => "f" "identificador" => "aff0030" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "<span class="elsevierStyleItalic">Maturity onset diabetes of the young</span>: de la base molecular al fenotipo clínico y el manejo adecuado" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "fuente" => "Adapted from Ref. <a class="elsevierStyleCrossRef" href="#bib0610">53</a>." "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1034 "Ancho" => 1667 "Tamanyo" => 149684 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Sulfonylurea receptor (SUR) components: 1 – SUR encoded by ABCC8 gene; 2 – potassium voltage-gated channel; Kir 6.20 – encoded by subfamily J member 11 (KCNJ11) gene.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Maturity-onset diabetes of the young (MODY) is a monogenic form of diabetes that comprises a heterogeneous group of disorders characterized by primary defect in pancreatic β-cell function, early onset (classically presenting before the age of 25) and autosomal dominant inheritance, with absence of autoimmunity or, for most of the cases, ketosis.<a class="elsevierStyleCrossRefs" href="#bib0350"><span class="elsevierStyleSup">1,2</span></a> Other monogenic forms of diabetes comprises neonatal diabetes, syndromic forms and mitochondrial diabetes (maternally inherited diabetes and deafness).<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">3</span></a> Commonly misdiagnosed as Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM), MODY has an estimated prevalence of 1–5% in the diabetic population, thought frequently undervalued.<a class="elsevierStyleCrossRefs" href="#bib0365"><span class="elsevierStyleSup">4,5</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The molecular basis of MODY was recognized a couple decades ago, since genetic mutations result in diabetes primarily through their effects on β-cell dysfunction. Moreover, the clinical features of patients with MODY are currently known to be heterogeneous, depending on the genetic etiology.<a class="elsevierStyleCrossRefs" href="#bib0375"><span class="elsevierStyleSup">6,7</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">In fact, 14 MODY subtypes has been described so far, referred from 1 to 14, according to the order of the discovery, with mutations in 14 different genes (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>, <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). Several of these genes encodes for transcription factors, namely: <span class="elsevierStyleItalic">hepatocyte nuclear factor</span> (HNF) 4α (related to MODY 1), HNF-1α (related to MODY 3), <span class="elsevierStyleItalic">insulin promoter factor 1</span> (IPF-1) (related to MODY 4), HNF-1β (related to MODY 5), <span class="elsevierStyleItalic">neurogenic differentiation factor 1</span> (NeuroD1), also known as <span class="elsevierStyleItalic">β-cell E-box transactivator 2</span> (BETA2) (related to MODY 6), <span class="elsevierStyleItalic">Kruppel-like factor 11</span> (KLF11) (related to MODY 7) and <span class="elsevierStyleItalic">paired box gene 4</span> (PAX 4) (related to MODY 9). With regard to the others, glucokinase (<span class="elsevierStyleItalic">GCK</span>) gene encodes GCK enzyme (related to MODY 2). Insulin (<span class="elsevierStyleItalic">INS</span>) gene encodes for proinsulin precursor of insulin (related to MODY 8). Carboxyl-ester lipase (<span class="elsevierStyleItalic">CEL</span>) gene encodes CEL lipase enzyme (related to MODY 10). B lymphoid tyrosine kinase (<span class="elsevierStyleItalic">BLK</span>) gene encodes BLK protein (related to MODY 11). ATP-binding cassette transporter sub-family C member 8 (<span class="elsevierStyleItalic">ABCC8</span>) gene encodes ABCC8 protein (related to MODY 12). Potassium voltage-gated channel subfamily J member 11 (<span class="elsevierStyleItalic">KCNJ11</span>) gene encodes human BIR (β-cell inward rectifier or Kir6.20) (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>) (related to MODY 13). Finally, Adaptor Protein Phosphotyrosine interacting with PH domain and Leucine zipper 1 <span class="elsevierStyleItalic">(APPL1</span>) gene (related to MODY 14) encodes APPL1 adapter protein.<a class="elsevierStyleCrossRefs" href="#bib0365"><span class="elsevierStyleSup">4,8</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0020" class="elsevierStylePara elsevierViewall">Among these, the most common MODY subtypes are MODY 3 and MODY 2. MODY 1, 5, and 4 are rare, whereas MODY 6–14 comprises a group of very rare forms of MODY.<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">5,8</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">MODY's early diagnosis still remains a challenge for physicians, with important future implications, since it will allow treatment optimization, prognosis definition and genetic counseling of family members.<a class="elsevierStyleCrossRefs" href="#bib0350"><span class="elsevierStyleSup">1,7</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">In this sense, this review intends to be an update of the state of art of all currently known MODY's subtypes and the way of dealing with, also seeking to disclose MODY's future management based on the latest research on this field.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Gene mutations involved in the different MODY's forms, the respective phenotype outcomes and management</span><p id="par0035" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">HNF-1α</span> and <span class="elsevierStyleItalic">GCK</span> products represents the most common forms of MODY phenotypes (30–65% and 30–50%, respectively), followed by <span class="elsevierStyleItalic">HNF-4α</span> (5–10%) and <span class="elsevierStyleItalic">HNF-1β</span> (<5%).<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">8</span></a> The remaining genetic subtypes, being rarer causes of MODY (<1%), have limited data available with few published literature.<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">8</span></a></p><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">HNF-1α and HNF-4α (MODY 3 and MODY 1)</span><p id="par0040" class="elsevierStylePara elsevierViewall">The hepatic transcription factors HNF-1α and HNF-4α are responsible for the gene's regulation in the liver, pancreatic islet cells, kidneys, and genital tissues.<a class="elsevierStyleCrossRefs" href="#bib0390"><span class="elsevierStyleSup">9–11</span></a> Mutations in the genes encoding these transcription factors may account for some MODY subtypes, such as MODY 3 and 1, respectively.<a class="elsevierStyleCrossRefs" href="#bib0390"><span class="elsevierStyleSup">9–11</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">In fact, in pancreatic β-cells, these transcription factors regulate the expression of the <span class="elsevierStyleItalic">INS</span> gene, as well as the expression of genes encoding proteins involved in the transport and metabolism of glucose.<a class="elsevierStyleCrossRefs" href="#bib0390"><span class="elsevierStyleSup">9,10,12</span></a> In the liver, these proteins regulate lipoprotein biosynthesis.<a class="elsevierStyleCrossRefs" href="#bib0390"><span class="elsevierStyleSup">9,10</span></a> The expression of HNF-1α is partially regulated by HNF-4α.<a class="elsevierStyleCrossRefs" href="#bib0400"><span class="elsevierStyleSup">11,13</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">The pathophysiological mechanisms of MODY related with mutations in the <span class="elsevierStyleItalic">HNF-1α</span> (MODY 3) and <span class="elsevierStyleItalic">HNF-4α</span> (MODY 1) genes are very similar, since <span class="elsevierStyleItalic">HNF-1α</span> expression is regulated by <span class="elsevierStyleItalic">HNF-4α</span>.<a class="elsevierStyleCrossRefs" href="#bib0400"><span class="elsevierStyleSup">11,13</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">Fasting hyperglycemia is relatively mild in these patients, albeit they have significantly higher glycemic levels 2<span class="elsevierStyleHsp" style=""></span>h after oral glucose overload compared to those with mutated <span class="elsevierStyleItalic">GCK</span>.<a class="elsevierStyleCrossRefs" href="#bib0405"><span class="elsevierStyleSup">12,14</span></a> In MODY 3 and MODY 1 hyperglycemia tends to increase over time and, thus, for most patients, pharmacological treatment with oral antidiabetic drugs (OADs) or insulin will be required (30–40% demands insulin).<a class="elsevierStyleCrossRefs" href="#bib0415"><span class="elsevierStyleSup">14,15</span></a> Evidence has shown that glucose-induced insulin secretion declines by 1–4% per year in patients with MODY 3.<a class="elsevierStyleCrossRefs" href="#bib0420"><span class="elsevierStyleSup">15,16</span></a> In addition, along with transient neonatal hyperinsulinemic hypoglycemia, macrosomia, and gestational diabetes, are also common features of these MODY subtypes.<a class="elsevierStyleCrossRefs" href="#bib0415"><span class="elsevierStyleSup">14,17</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">These patients may have the full spectrum of diabetes complications. In fact, microvascular complications, particularly retinopathy and nephropathy, are as frequent as in T1DM or T2DM<a class="elsevierStyleCrossRefs" href="#bib0415"><span class="elsevierStyleSup">14,16</span></a> (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).</p><p id="par0065" class="elsevierStylePara elsevierViewall">In addition to the effects in β-cells, since <span class="elsevierStyleItalic">HNF-1α</span> and <span class="elsevierStyleItalic">HNF-4α</span> are also expressed in other organs, these subjects present extrapancreatic manifestations, affecting renal and hepatic functions.<a class="elsevierStyleCrossRefs" href="#bib0405"><span class="elsevierStyleSup">12,18</span></a> In fact, reduced glucose renal reabsorption (<span class="elsevierStyleItalic">i.e.</span>, a low renal threshold for glucose) and glycosuria represents a MODY 3 hallmark.<a class="elsevierStyleCrossRefs" href="#bib0405"><span class="elsevierStyleSup">12,19</span></a> On the other hand, HNF-4α deficiency is related with a reduction in triglyceride concentration, as well as in serum levels of apolipoproteins AI, AII, CIII, and lipoprotein Lp(a)<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">20</span></a> (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).</p><p id="par0070" class="elsevierStylePara elsevierViewall">In regard to treatment, an important distinctive feature of <span class="elsevierStyleItalic">HNF-1α</span> mutations is the particularly sensitivity to the hypoglycemic effects of sulfonylureas.<a class="elsevierStyleCrossRefs" href="#bib0405"><span class="elsevierStyleSup">12,21</span></a> In a randomized cross-over study comparing individuals diagnosed with MODY 3 with those with T2DM, a <span class="elsevierStyleItalic">4-fold</span> increased response to <span class="elsevierStyleItalic">gliclazide</span> was found for MODY 3 subjects, whereas the response to metformin was similar in both groups.<a class="elsevierStyleCrossRef" href="#bib0450"><span class="elsevierStyleSup">21</span></a><span class="elsevierStyleItalic">Nateglinide</span> has also been used in these patients, suggesting that prandial secretagogues may be a useful alternative.<a class="elsevierStyleCrossRefs" href="#bib0425"><span class="elsevierStyleSup">16,22</span></a> Although glycemic control could be sustained for several years, most patients will eventually move toward insulin treatment due to a progressive β-cell dysfunction.<a class="elsevierStyleCrossRef" href="#bib0425"><span class="elsevierStyleSup">16</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">Similarly, a low dose of sulfonylureas (12.5% or less of the maximum authorized dose) seems to be an effective treatment for patients with <span class="elsevierStyleItalic">HNF-4α</span> mutations.<a class="elsevierStyleCrossRef" href="#bib0415"><span class="elsevierStyleSup">14</span></a></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">GCK (MODY 2)</span><p id="par0080" class="elsevierStylePara elsevierViewall">GCK enzyme is expressed, at high concentrations, in pancreatic and hepatic cells.<a class="elsevierStyleCrossRef" href="#bib0435"><span class="elsevierStyleSup">18</span></a> It catalyses the phosphate transfer from ATP to glucose, generating glucose-6-phosphate, whose metabolism, in turn, stimulates the secretion of insulin by β-cells.<a class="elsevierStyleCrossRefs" href="#bib0435"><span class="elsevierStyleSup">18,23</span></a> Therefore, GCK acts as a “glucose sensor” in β-cells. Moreover, in the liver, GCK plays a key role in the glucose hepatic storage as glycogen, particularly in the postprandial state.<a class="elsevierStyleCrossRefs" href="#bib0425"><span class="elsevierStyleSup">16,18</span></a> Heterozygous inactivating mutations in the <span class="elsevierStyleItalic">GCK</span> gene leads to a partial deficiency of this enzyme, which is responsible for MODY 2; homozygous inactivating mutations induce the complete <span class="elsevierStyleItalic">GCK</span> deficiency and consequently, neonatal diabetes mellitus.<a class="elsevierStyleCrossRefs" href="#bib0365"><span class="elsevierStyleSup">4,23</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">GCK</span>-related MODY (MODY 2) is a common form, especially in children and women with history of gestational diabetes.<a class="elsevierStyleCrossRefs" href="#bib0405"><span class="elsevierStyleSup">12,16</span></a> In MODY 2, hyperglycemia is mild, non-progressive, and asymptomatic at the time of diagnosis, not associated with vascular complications common in other types of diabetes.<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">7,24</span></a> Less than 50% of genetic carriers will develop diabetes, whereas nearly 50% of women may develop gestational diabetes.<a class="elsevierStyleCrossRef" href="#bib0435"><span class="elsevierStyleSup">18</span></a> Noteworthy, in MODY 2 families, birth weight of newborn infants relies on both fetal and maternal mutation status. In the absence of GCK mutation in the baby, he may be at risk for macrosomia and increased birth weight in approximately 500<span class="elsevierStyleHsp" style=""></span>g, as a result of the exposure to maternal hyperglycemia. When the mutation is inherited from the mother, baby has similar homeostatic glucose set points and, thus, normal birth weight. On the other hand, if the mutation is inherited from the father, insulin secretion in the baby is reduced and birth weight is decreased in about 500<span class="elsevierStyleHsp" style=""></span>g<a class="elsevierStyleCrossRef" href="#bib0425"><span class="elsevierStyleSup">16</span></a> (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).</p><p id="par0090" class="elsevierStylePara elsevierViewall">The general consensus has pointed out that for most patients with MODY 2 pharmacological treatment will not be necessary.<a class="elsevierStyleCrossRefs" href="#bib0405"><span class="elsevierStyleSup">12,14</span></a> Exceptionally, some subjects will demand insulin therapy, namely in cases of severe hyperglycemia (≤2% of MODY 2) and pregnant women, in which insulin treatment could be necessary in order to prevent excessive fetal growth.<a class="elsevierStyleCrossRefs" href="#bib0405"><span class="elsevierStyleSup">12,18</span></a></p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">HNF-1β (MODY 5)</span><p id="par0095" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">HNF-1β</span> gene belongs to the homeodomain-containing family of transcription factors, being involved in embryonic development of several organs, including kidneys, urinary tract, liver, and pancreas.<a class="elsevierStyleCrossRef" href="#bib0470"><span class="elsevierStyleSup">25</span></a> Mutations in this gene may account for another MODY subtype, designated MODY 5.<a class="elsevierStyleCrossRefs" href="#bib0435"><span class="elsevierStyleSup">18,26</span></a> Its plausible that the affected subjects may develop renal disease, characterized by renal cysts, renal dysplasia, renal malformations, or hypoplastic glomerulocystic kidney disease. In fact, <span class="elsevierStyleItalic">HNF-1β</span> mutation is specifically associated with non-diabetic renal disease, with renal function ranging from mild to terminal renal insufficiency.<a class="elsevierStyleCrossRefs" href="#bib0425"><span class="elsevierStyleSup">16,27</span></a> Pancreatic atrophy, abnormalities of the female genital tract and abnormal liver function among affected individuals can also be observed.<a class="elsevierStyleCrossRefs" href="#bib0415"><span class="elsevierStyleSup">14,25</span></a> Birth weight is reduced by nearly 900<span class="elsevierStyleHsp" style=""></span>g due to a decreased insulin secretion in uterus.<a class="elsevierStyleCrossRefs" href="#bib0365"><span class="elsevierStyleSup">4,7</span></a> About a half of MODY 5 subjects present diabetes at youth, as those with MODY 3.<a class="elsevierStyleCrossRef" href="#bib0415"><span class="elsevierStyleSup">14</span></a> However, unlike the latter, <span class="elsevierStyleItalic">HNF-1β</span> mutations are related with insulin resistance and hyperuricemia.<a class="elsevierStyleCrossRefs" href="#bib0425"><span class="elsevierStyleSup">16,28</span></a></p><p id="par0100" class="elsevierStylePara elsevierViewall">Thereby, the low insulin sensitivity of MODY 5 patients suggests an insulin sensitizer, such as metformin or pioglitazone, as the oral drug of choice.<a class="elsevierStyleCrossRef" href="#bib0485"><span class="elsevierStyleSup">28</span></a> Actually, these subjects do not respond particularly well to sulfonylureas, and usually require early insulin therapy.<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">7,24</span></a></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">IPF-1 (MODY 4)</span><p id="par0105" class="elsevierStylePara elsevierViewall">IPF-1 is a pancreatic homeodomain transcription factor (also known as IDX-1, STF-1 and PDX-1) that regulates both early pancreatic development and the expression of key endocrine β-cell-specific genes, most notably insulin.<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">29</span></a> Targeted disruption of the <span class="elsevierStyleItalic">IPF-1</span> gene in mice results in pancreatic agenesis. In a human subject with pancreatic agenesis, this phenotype was attributable to homozygosity for an inactivating mutation of <span class="elsevierStyleItalic">IPF-1</span> gene. Heterozygous carriers of the mutation develop MODY 4.<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">29</span></a></p><p id="par0110" class="elsevierStylePara elsevierViewall">The current insights of <span class="elsevierStyleItalic">IPF-1</span>-related MODY (MODY 4) are mainly based on studies in a few families, including a family with MODY 2 and MODY 4 combined mutations.<a class="elsevierStyleCrossRefs" href="#bib0490"><span class="elsevierStyleSup">29–32</span></a> Molecular studies in a child with neonatal diabetes and exocrine pancreatic insufficiency – as a result of congenital agenesis of the pancreas – revealed the presence of the homozygous form of the <span class="elsevierStyleItalic">IPF-1</span> mutation; the parents were carriers of the heterozygous form of this mutation.<a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">33</span></a> The whole family evaluation had revealed a high prevalence of a mild form of diabetes, with autosomal dominant transmission, along with the heterozygous mutation in the <span class="elsevierStyleItalic">IPF-1</span>.<a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">33</span></a> For the carriers of this mutation, the onset of diabetes may occur at more advanced ages (around the age of 35), compared to other MODY subtypes, and can be treated with diet, OAD and/or possibly insulin, for the most severe cases.<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">7,33</span></a> In an Italian family with Pro to Thr substitution (P33T) in the IPF1 transactivation domain the clinical phenotype goes from gestational diabetes, MODY4 to T2DM.<a class="elsevierStyleCrossRef" href="#bib0500"><span class="elsevierStyleSup">31</span></a></p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">NeuroD1 (MODY 6)</span><p id="par0115" class="elsevierStylePara elsevierViewall">The transcription factor NeuroD1 (also known as BETA2) was isolated based on its ability to activate the transcription of the <span class="elsevierStyleItalic">INS</span> gene, being fundamental for the normal development of pancreatic islets.<a class="elsevierStyleCrossRef" href="#bib0515"><span class="elsevierStyleSup">34</span></a> Mutations in NeuroD1 encoding genes may be responsible for another MODY subtype, designated MODY 6.<a class="elsevierStyleCrossRef" href="#bib0435"><span class="elsevierStyleSup">18</span></a></p><p id="par0120" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">NeuroD1</span>-related MODY is characterized by permanent neonatal diabetes and a consistent pattern of neurological abnormalities including cerebellar hypoplasia, learning difficulties, sensorineural deafness, and visual impairment.<a class="elsevierStyleCrossRefs" href="#bib0425"><span class="elsevierStyleSup">16,35,36</span></a> This syndrome highlights the key role of <span class="elsevierStyleItalic">NeuroD1</span> in both the development of the endocrine pancreas and the central nervous system in humans.<a class="elsevierStyleCrossRef" href="#bib0525"><span class="elsevierStyleSup">36</span></a> The optimal therapeutic approach is yet to be disclosed, since the related literature is scarce though it suggests OAD or insulin requirement.<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">7,35</span></a></p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">KLF11 (MODY 7)</span><p id="par0125" class="elsevierStylePara elsevierViewall">KLF11 is a transcription factor present in pancreatic β-cells that acts as a negative regulator of exocrine cell growth.<a class="elsevierStyleCrossRef" href="#bib0530"><span class="elsevierStyleSup">37</span></a> KLF11 also plays a key role as a glucose-induced regulator of <span class="elsevierStyleItalic">INS</span> gene, through binding to insulin promoter, as other MODY subtypes already mentioned.<a class="elsevierStyleCrossRef" href="#bib0535"><span class="elsevierStyleSup">38</span></a> In addition, increased repression of the catalase 1 promoter has been reported, suggesting a role in the clearance of free radicals that can turn these cells more susceptible to oxidative stress.<a class="elsevierStyleCrossRefs" href="#bib0365"><span class="elsevierStyleSup">4,37</span></a><span class="elsevierStyleItalic">KLF11</span>-related MODY is often associated with pancreatic malignancy.<a class="elsevierStyleCrossRef" href="#bib0530"><span class="elsevierStyleSup">37</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">CEL (MODY 8)</span><p id="par0130" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">CEL</span> gene encodes CEL enzyme involved in digesting milk and hydrolyzing dietary esters in duodenum and is also responsible for the hydration and absorption of cholesterol and liposoluble molecules.<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">39</span></a> Current literature supports the involvement of CEL, also known as bile salt-dependent lipase (BSDL), in the pathophysiology of these pancreatic diseases.<a class="elsevierStyleCrossRef" href="#bib0545"><span class="elsevierStyleSup">40</span></a> This enzyme is normally secreted by the exocrine pancreas and is diverted within the intestinal lumen to participate in the hydrolysis of dietary lipids. CEL is not transcribed into β-cells, being mainly expressed in pancreatic acinar tissues and lactating mammary glands.<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">39</span></a> Despite the underlying pathophysiological mechanisms are yet to be fully understood, mutations in this gene are responsible for an exocrine and endocrine pancreatic dysfunction associated with another MODY subtype, MODY 8.<a class="elsevierStyleCrossRefs" href="#bib0365"><span class="elsevierStyleSup">4,39,41</span></a></p><p id="par0135" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">CEL</span>-related MODY is associated with pancreatic atrophy, fibrosis and lipomatosis together with exocrine insufficiency and later endocrine dysfunction and diabetes. Fat infiltration is an early event in non-diabetic carriers of mutations in the variable number of tandem repeat (VNTR) region of CEL, with signs of exocrine dysfunction that meet the criteria for chronic pancreatitis.<a class="elsevierStyleCrossRefs" href="#bib0545"><span class="elsevierStyleSup">40,41</span></a> Dyslipidemia is associated with an inflammatory status in patients with diabetes. It is known that branched fatty esters of hydroxyl fatty acids (FAHFAs) present protective effects against diabetes, with anti-inflammatory activities.<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">42</span></a> A recent study demonstrates that FAHFAs are the preferred substrates for CEL.<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">42</span></a> Any perturbation in the BSDL variant homeostasis, associated with different enzymatic properties, leading to its retention within the cell, could induce active degradation of these protective endogenous FAHFAs. Suppression of the anti-inflammatory activity of FAHFAs upon BSDL hydrolysis may cause diabetes.<a class="elsevierStyleCrossRef" href="#bib0545"><span class="elsevierStyleSup">40</span></a> Overall, these data suggested that deletion in VNTR, such as c.1686delT, leads to modification of the CEL specificity. Therefore, it can be hypothesized that any BSDL/CEL variant with VNTR mutations may have different specificity from that of the non-mutated enzyme.<a class="elsevierStyleCrossRef" href="#bib0545"><span class="elsevierStyleSup">40</span></a></p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">PAX4 (MODY 9)</span><p id="par0140" class="elsevierStylePara elsevierViewall">PAX 4 is a transcription factor member of PAX family that regulates fetal development, cancer growth and also represses the promoter activity of insulin and glucagon.<a class="elsevierStyleCrossRef" href="#bib0560"><span class="elsevierStyleSup">43</span></a> PAX4 is required for the regeneration of β-cells in adults and its mutation blocks or inhibits β-cell growth and proliferation.<a class="elsevierStyleCrossRefs" href="#bib0560"><span class="elsevierStyleSup">43,44</span></a> In this sense, mutations in this gene leads to impaired glucose-dependent insulin secretion and were reported as the cause of a monogenetic form of diabetes, designated MODY 9.<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">44,45</span></a> Some PAX4 mutations induced increased susceptibility of β-cell to apoptosis upon high glucose exposure. <span class="elsevierStyleItalic">PAX4</span>-related MODY 9 has been linked with ketosis-prone diabetes.<a class="elsevierStyleCrossRef" href="#bib0575"><span class="elsevierStyleSup">46</span></a></p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">INS (MODY 10)</span><p id="par0145" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">INS</span> gene encodes the proinsulin precursor of insulin molecule.<a class="elsevierStyleCrossRefs" href="#bib0580"><span class="elsevierStyleSup">47,48</span></a> It has been reported that a mutation in this gene cause a defect in the <span class="elsevierStyleItalic">nuclear factor kappa-light-chain-enhancer of activated β-cells</span> (NF-κB) transcription factor, leading to reduced structural stability of insulin molecule associated with a very rare form of MODY subtype, designated as MODY 10.<a class="elsevierStyleCrossRefs" href="#bib0365"><span class="elsevierStyleSup">4,49</span></a><span class="elsevierStyleItalic">INS</span>-related MODY (MODY 10) is also linked with neonatal diabetes.<a class="elsevierStyleCrossRef" href="#bib0585"><span class="elsevierStyleSup">48</span></a></p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">BLK (MODY 11)</span><p id="par0150" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">BLK-B</span> gene, expressed in pancreatic β-cells, encodes a nonreceptor tyrosine kinase of the <span class="elsevierStyleItalic">src</span> family of proto-oncogenes and plays a major role in thymopoiesis in immature T cells.<a class="elsevierStyleCrossRefs" href="#bib0365"><span class="elsevierStyleSup">4,50</span></a> Moreover, it promotes the glucose-dependent insulin synthesis and secretion through the upregulation of PDX-1 and NKx-6 transcription factors.<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">50</span></a> The <span class="elsevierStyleItalic">BLK</span> gene mutation mainly affects MIN6 β-cells (a highly differentiated β-cell line) and, therefore, is responsible for another MODY subtype, MODY 11.<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">50</span></a></p><p id="par0155" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">BLK</span>-related MODY is linked with a higher prevalence of the obese phenotype compared with other MODY's individuals.<a class="elsevierStyleCrossRef" href="#bib0600"><span class="elsevierStyleSup">51</span></a></p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">ABCC8 (MODY 12)</span><p id="par0160" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">ABCC8</span> gene encodes the sulfonylurea receptor 1 (SUR 1) subunit of ATP-sensitive potassium (K<span class="elsevierStyleInf">ATP</span>) channel found across pancreatic β-cells membrane, being involved in the insulin secretion process<a class="elsevierStyleCrossRefs" href="#bib0605"><span class="elsevierStyleSup">52,53</span></a> (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). Mutations in this gene results in sulfonylureas responsive MODY, termed MODY 12, which clinical features are similar to those of HNF-1α/4α related MODY, being associated with neonatal diabetes, and can occur due to both activating or inactivating mutations of <span class="elsevierStyleItalic">ABCC8</span> gene.<a class="elsevierStyleCrossRefs" href="#bib0365"><span class="elsevierStyleSup">4,52</span></a></p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">KCNJ11 (MODY 13)</span><p id="par0165" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">KCNJ11</span> gene encodes Kir6.20 subunit of the pancreatic β-cells ATP-sensitive potassium (K<span class="elsevierStyleInf">ATP</span>) channel, playing a role in structure modulation of this channel and, thus, in insulin secretion<a class="elsevierStyleCrossRef" href="#bib0615"><span class="elsevierStyleSup">54</span></a> (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). Therefore, <span class="elsevierStyleItalic">KCNJ11</span> gene mutations, responsible for another MODY subtype, designated MODY 13, leads to impaired fasting glucose or impaired glucose tolerance, due to the disrupted subunit interaction. Likewise <span class="elsevierStyleItalic">INS</span>-related MODY (MODY 10) and <span class="elsevierStyleItalic">ABCC8</span>-related MODY (MODY 12), MODY 13 is associated with neonatal diabetes being also sensitive to sulfonylurea therapy.<a class="elsevierStyleCrossRefs" href="#bib0365"><span class="elsevierStyleSup">4,54</span></a></p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">APPL1 (MODY 14)</span><p id="par0170" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">APPL1</span> gene is widely expressed in all insulin target tissues and organs including the liver, adipose tissue, skeletal muscle, and pancreas.<a class="elsevierStyleCrossRef" href="#bib0620"><span class="elsevierStyleSup">55</span></a> In pancreatic islets, APPL1 adapter protein co-localizes with insulin, indicating that is abundantly expressed in pancreatic β-cells where it acts as a physiological regulator of insulin secretion, binding to AKT2, a key molecule in the insulin signaling pathway. Mutations in <span class="elsevierStyleItalic">APPL1</span> gene can cause APPL1 loss-of-function leading to MODY 14 phenotype.<a class="elsevierStyleCrossRef" href="#bib0620"><span class="elsevierStyleSup">55</span></a> In addition, evidences from a zebrafish-based model have also linked <span class="elsevierStyleItalic">APPL1</span> overexpression with dysmorphic phenotypes and delay in the development.<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">56</span></a></p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">MODY-x</span><p id="par0175" class="elsevierStylePara elsevierViewall">A significant percentage of patients with clinical characteristics of MODY, has an unknown causative gene (MODY-x).<a class="elsevierStyleCrossRefs" href="#bib0425"><span class="elsevierStyleSup">16,57</span></a> The identification of additional genes related to MODY will clarify the molecular basis of diabetes in these patients. Frayling et al. conducted a multicenter study with several researchers from Oxford, Lille and Malmo, stressing the need to continue the search for new mutations in families with MODY-x.<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">58</span></a> In this study, 3 loci with Heterogeneity Logarithm of Odds (HLOD) scores >1.0 on chromosomes 3, 16 and 20 were identified, albeit the required level of significance of 3.3 has not been achieved. The identification of these 3 loci confirms the vast genetic heterogeneity in families with MODY-x.<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">58</span></a></p><p id="par0180" class="elsevierStylePara elsevierViewall">Further research will be needed in order to get a deeper knowledge on MODY's pathophysiological mechanisms and, therefore, allow an individualized approach accordingly to each subtype, with the subsequent improvement on patient outcomes.<a class="elsevierStyleCrossRefs" href="#bib0365"><span class="elsevierStyleSup">4,7</span></a></p></span></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Diagnosis</span><p id="par0185" class="elsevierStylePara elsevierViewall">First and foremost, the diagnosis of MODY requires a high index of suspicion.<a class="elsevierStyleCrossRefs" href="#bib0640"><span class="elsevierStyleSup">59,60</span></a> In fact, MODY's diagnosis still remains a challenge, since this heterogeneous group of monogenic disorders comprises a large clinical spectrum and it usually overlaps with other types of diabetes. Consequently, many patients remain undiagnosed. Although MODY affects only a small part of diabetic subjects and its diagnosis is rare, it has important implications for the prognosis and treatment of patients, as well as for family members genetic counseling.<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">24</span></a></p><p id="par0190" class="elsevierStylePara elsevierViewall">The definitive diagnosis of MODY requires a molecular genetic study. These genetic tests are performed by direct sequencing of MODY genes (sensitivity >99%).<a class="elsevierStyleCrossRefs" href="#bib0465"><span class="elsevierStyleSup">24,60</span></a> The standard approach includes sequential screening of the three most common MODY genes: <span class="elsevierStyleItalic">HNF-1α</span>, <span class="elsevierStyleItalic">GCK</span>, and <span class="elsevierStyleItalic">HNF-4α</span>.<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">61,62</span></a> However, with the advent of next-generation sequencing (NGS) technology, there has been a significant improvement in the speed and scalability of the genetic sequencing and an extended profile is also currently available.<a class="elsevierStyleCrossRefs" href="#bib0640"><span class="elsevierStyleSup">59,61</span></a></p><p id="par0195" class="elsevierStylePara elsevierViewall">After a strong clinical suspicion, the genetic mutation diagnosis must be performed in order to accurately define MODY subtype and lead to the identification of other affected family members. Furthermore, the optimal treatment and risk for diabetes complications relies on the genetic defect.<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">7,59</span></a></p><p id="par0200" class="elsevierStylePara elsevierViewall">Although <span class="elsevierStyleItalic">de novo</span> mutations can arise, cascade screening of family members is essential to ensure those with diabetes get the correct diagnostic label and those at risk of inheriting the mutation are tested for diabetes and/or consider predictive genetic testing.<a class="elsevierStyleCrossRefs" href="#bib0425"><span class="elsevierStyleSup">16,59</span></a></p><p id="par0205" class="elsevierStylePara elsevierViewall">Indications for genetic testing for MODY includes the following major diagnosis criteria widely accepted<a class="elsevierStyleCrossRefs" href="#bib0365"><span class="elsevierStyleSup">4,63</span></a>:<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">-</span><p id="par0210" class="elsevierStylePara elsevierViewall">Hyperglycemia usually diagnosed before the age of 25 in at least 1 and ideally 2 family members;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">-</span><p id="par0215" class="elsevierStylePara elsevierViewall">Autosomal dominant inheritance, with a vertical transmission of diabetes through at least 3 generations, and a similar phenotype shared by diabetic family members;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">-</span><p id="par0220" class="elsevierStylePara elsevierViewall">Absence of insulin therapy at least 5 years after diagnosis or significant C-peptide levels even in a patient on insulin treatment;</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">-</span><p id="par0225" class="elsevierStylePara elsevierViewall">Insulin levels that are often in the normal range, although inappropriately low for the degree of hyperglycemia, suggesting a primary defect in β-cell function;</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">-</span><p id="par0230" class="elsevierStylePara elsevierViewall">Overweight or obesity is rarely associated (and is not required for the development of diabetes).</p></li></ul></p><p id="par0235" class="elsevierStylePara elsevierViewall">Notwithstanding, other remarkable MODY features encompasses: mild diabetes on presentation without significant ketosis; absence of pancreatic autoantibodies; glycosuria inappropriately observed along with euglycemia or mild hyperglycemia, in the absence of albuminuria and poorly controlled diabetes (low renal threshold that results in glycosuria is a typical MODY 3 feature); marked sensitivity to insulin secretagogues (sulfonylureas) in HNF-1α and HNF-4α subtypes; as well as no typical features of TIDM or T2DM.<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">2,4,16</span></a></p><p id="par0240" class="elsevierStylePara elsevierViewall">In order to achieve a more cost-effective approach, avoiding unnecessary genetic testing, a prediction model was developed to discriminate MODY patients from T1DM and T2DM, using logistic regression for that propose.<a class="elsevierStyleCrossRef" href="#bib0665"><span class="elsevierStyleSup">64</span></a> The model, referred as <span class="elsevierStyleItalic">The MODY Probability Calculator</span>, offers a more standardized approach to select individuals for genetic testing. This online calculator (developed by Beverley Shields, University of Exeter; available at: <a href="https://www.diabetesgenes.org/mody-probability-calculator/"><span class="elsevierStyleUnderline">https://www.diabetesgenes.org/mody-probability-calculator/</span></a>), combines broad clinical information to predict the probability of testing positive for MODY and includes: age at diagnosis, body mass index, HbA1c level, therapy (insulin or OADs) and family history. When matched with traditional criteria, the prediction model improved the sensitivity and specificity for identifying MODY. However, this model was only validated in one European cohort of Caucasian individuals, lacking, therefore, a more generalized validation to other ethnicities.<a class="elsevierStyleCrossRef" href="#bib0665"><span class="elsevierStyleSup">64</span></a></p><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Differential diagnosis</span><p id="par0245" class="elsevierStylePara elsevierViewall">In view of the high cost and limited availability of genetic testing, substantial efforts have recently been made to identify a specific, inexpensive and readily disposable non-genetic biomarker to discriminate between MODY and other types of diabetes. Along with the clinical features, it would aid in prioritizing patient for genetic testing (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">7,59,65</span></a></p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0250" class="elsevierStylePara elsevierViewall">It has been documented that in adults with diabetes for more than 5 years, the urinary C-peptide/creatinine ratio is higher in MODY 3 or MODY 1 when compared to T1DM (sensitivity 97% and specificity 96%).<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">66</span></a> Furthermore, other biomarkers proposed for discrimination between MODY 3, MODY 1 and T2DM include 1,5-anhydroglucitol, the complement factors C5 and C8, apolipoprotein M and transthyretin, although none of them have enough specificity or sensitivity to be clinically.<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">66</span></a> So far, one of the most promising biomarkers is <span class="elsevierStyleItalic">high-sensitivity</span> C-reactive protein (<span class="elsevierStyleItalic">hs</span>-CRP), which is significantly lower in MODY 3 than in TIDM, T2DM, MODY 2 and even in non-diabetic individuals.<a class="elsevierStyleCrossRefs" href="#bib0680"><span class="elsevierStyleSup">67,68</span></a></p><p id="par0255" class="elsevierStylePara elsevierViewall">In fact, for most cases, the onset of MODY arises in childhood or adolescence, resembling T1DM. However, in these patients there is no complete lack of insulin and, therefore, insulin therapy will not be required, at least at an early stage of the disease. In some patients OADs or insulin therapy may be necessary, as a rapid progression of hyperglycemia can occur.<a class="elsevierStyleCrossRefs" href="#bib0405"><span class="elsevierStyleSup">12,16</span></a> The presence of autoantibodies for T1DM often precludes further testing for monogenic diabetes, since it makes MODY very unlikely, albeit positive autoantibodies in patients with monogenic diabetes has been reported.<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">69</span></a> Thereby, a biomarker screening such as the combination of C-peptide and antibody screening (autoantibodies to GAD, insulin, the tyrosine phosphatases IA-2 and IA-2b, and ZnT8) should be performed prior to consideration of genetic testing for MODY.<a class="elsevierStyleCrossRefs" href="#bib0405"><span class="elsevierStyleSup">12,59</span></a> Actually, recent population-based studies have pointed toward this biomarker screening as an easy and cost-effective approach capable to discriminate patients with MODY.<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">65</span></a></p><p id="par0260" class="elsevierStylePara elsevierViewall">On the other hand, it is more difficult to differentiate between MODY and T2DM. The absence of insulin resistance features, particularly in adolescents with presumed T2DM, is suspicious for MODY, though no biochemical tests that reliably differentiate between these two diseases are currently available.<a class="elsevierStyleCrossRefs" href="#bib0415"><span class="elsevierStyleSup">14,16</span></a> Usually, MODY behaves in the same fashion as an adult T2DM but has some specific features in the glycemic control MODY.</p></span></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Conclusion</span><p id="par0265" class="elsevierStylePara elsevierViewall">MODY is a genetically and clinically heterogeneous group of disorders. Its identification still remains a challenge for physicians, being largely underdiagnosed, though it has important implications for the individual and their families.</p><p id="par0270" class="elsevierStylePara elsevierViewall">Recent advances on the genetic determinants and pathophysiology of MODY allowed a better understanding of its underlying molecular mechanisms and, therefore, have been very promising and insightful, providing us several profitable approaches in this field. Further studies will make possible to set up new therapeutic strategies, with drugs able to prevent, correct or at least delay the decline of pancreatic β-cell function. Moreover, with the sustained increase of genomic and metabolomic development, rapid screening tools for MODY mutations will become readily available and a self-directed assessment will afford for a more personalized treatment and, ultimately, for a better patient care.</p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Authors’ contribution</span><p id="par0275" class="elsevierStylePara elsevierViewall">All the authors contributed equally to this work.</p></span><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Funding sources</span><p id="par0280" class="elsevierStylePara elsevierViewall">The authors have no funding to disclose related to this review.</p></span><span id="sec0110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Conflict of interests</span><p id="par0285" class="elsevierStylePara elsevierViewall">The authors declare no conflict of interests.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres1306905" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1206743" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1306906" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1206744" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Gene mutations involved in the different MODY's forms, the respective phenotype outcomes and management" "secciones" => array:14 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "HNF-1α and HNF-4α (MODY 3 and MODY 1)" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "GCK (MODY 2)" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "HNF-1β (MODY 5)" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "IPF-1 (MODY 4)" ] 4 => array:2 [ "identificador" => "sec0035" "titulo" => "NeuroD1 (MODY 6)" ] 5 => array:2 [ "identificador" => "sec0040" "titulo" => "KLF11 (MODY 7)" ] 6 => array:2 [ "identificador" => "sec0045" "titulo" => "CEL (MODY 8)" ] 7 => array:2 [ "identificador" => "sec0050" "titulo" => "PAX4 (MODY 9)" ] 8 => array:2 [ "identificador" => "sec0055" "titulo" => "INS (MODY 10)" ] 9 => array:2 [ "identificador" => "sec0060" "titulo" => "BLK (MODY 11)" ] 10 => array:2 [ "identificador" => "sec0065" "titulo" => "ABCC8 (MODY 12)" ] 11 => array:2 [ "identificador" => "sec0070" "titulo" => "KCNJ11 (MODY 13)" ] 12 => array:2 [ "identificador" => "sec0075" "titulo" => "APPL1 (MODY 14)" ] 13 => array:2 [ "identificador" => "sec0080" "titulo" => "MODY-x" ] ] ] 6 => array:3 [ "identificador" => "sec0085" "titulo" => "Diagnosis" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0090" "titulo" => "Differential diagnosis" ] ] ] 7 => array:2 [ "identificador" => "sec0095" "titulo" => "Conclusion" ] 8 => array:2 [ "identificador" => "sec0100" "titulo" => "Authors’ contribution" ] 9 => array:2 [ "identificador" => "sec0105" "titulo" => "Funding sources" ] 10 => array:2 [ "identificador" => "sec0110" "titulo" => "Conflict of interests" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2019-03-01" "fechaAceptado" => "2019-07-09" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1206743" "palabras" => array:6 [ 0 => "Genetics" 1 => "Maturity onset diabetes of the young" 2 => "Monogenic diabetes" 3 => "Insulin" 4 => "Mutation" 5 => "Pancreatic β-cell" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1206744" "palabras" => array:6 [ 0 => "Genética" 1 => "<span class="elsevierStyleItalic">Maturity onset diabetes of the young</span>" 2 => "Diabetes monogénica" 3 => "Insulina" 4 => "Mutación" 5 => "Células β-pancreáticas" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Maturity-onset diabetes of the young (MODY) comprises a heterogeneous group of monogenic disorders characterized by primary defect in pancreatic β-cell function, early onset and autosomal dominant inheritance, accounting for about 1–5% of all diabetes diagnoses. Mutations in 14 genes are responsible for the majority of all MODY cases described so far. The clinical phenotype relies on genetic defects, with important implications in the optimal treatment and prognosis definition. MODY's early diagnosis remains a challenge, since this group of inherited disorders comprises a large clinical spectrum and it usually overlaps with other types of diabetes, requiring a high index of suspicion even if the definitive statement demands a molecular genetic study.</p><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Recent advances on the genetic determinants and pathophysiology of MODY have allowed a better understanding of its underlying molecular mechanisms, providing a proper genetic counseling and early diagnosis. These new management insights will make possible to set up new therapeutic strategies, with drugs able to prevent, correct or at least delay the decline of pancreatic β-cell function, thus affording for a more personalized treatment and, ultimately, for a better patient care.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">La diabetes tipo MODY (del inglés, <span class="elsevierStyleItalic">maturity onset diabetes of the young</span>) comprende un grupo heterogéneo de enfermedades monogénicas caracterizadas por un defecto primario de la función de las células β-pancreáticas, con inicio precoz y herencia autosómica dominante, que representa aproximadamente el 1-5% de las diabetes diagnosticadas. Las mutaciones descritas hasta la actualidad en 14 genes son responsables de la mayoría de los casos de la diabetes tipo MODY. El fenotipo clínico depende del defecto genético, y su identificación es importante para definir el tratamiento y el pronóstico. El diagnóstico temprano de la diabetes tipo MODY sigue siendo un reto, puesto que abarca un largo espectro de manifestaciones que se solapan con las de otros tipos de diabetes, exigiendo así un elevado grado de sospecha clínica y el diagnóstico definitivo necesita del estudio genético molecular.</p><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Los progresos recientes en el conocimiento de los determinantes genéticos y de la fisiopatología de la diabetes tipo MODY han permitido una mejor comprensión de los mecanismos moleculares subyacentes de estos procesos, y han facilitado un adecuado asesoramiento genético y el diagnóstico precoz. Estos nuevos conocimientos el abordaje permitirán el desarrollo de nuevas estrategias terapéuticas con fármacos capaces de prevenir, reparar o al menos retrasar el deterioro de la función de las células β-pancreáticas. Todo ello posibilitará un tratamiento más personalizado y, en última instancia, una mejor atención del paciente.</p></span>" ] ] "multimedia" => array:4 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1297 "Ancho" => 2167 "Tamanyo" => 218906 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">β-Cell transcription factor network.</p>" ] ] 1 => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "fuente" => "Adapted from Ref. <a class="elsevierStyleCrossRef" href="#bib0610">53</a>." "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1034 "Ancho" => 1667 "Tamanyo" => 149684 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Sulfonylurea receptor (SUR) components: 1 – SUR encoded by ABCC8 gene; 2 – potassium voltage-gated channel; Kir 6.20 – encoded by subfamily J member 11 (KCNJ11) gene.</p>" ] ] 2 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">MODY, maturity-onset diabetes of the young; OADs, oral antidiabetic drugs; OGTT, oral glucose tolerance test; Apo AI, AII and CIII, apolipoproteins AI, AII and CIII; Lp(a), lipoprotein Lp(a); TG, triglycerides; HNF, hepatocyte nuclear factor; GCK, Glucokinase; IPF-1, insulin promoter factor-1; NeuroD1, neurogenic differentiation factor 1; BETA2, β-cell E-box transactivator 2; KLF11, Kruppel-like factor 11; CEL, bile salt dependent lipase; PAX 4, paired box gene 4; INS, insulin; BLK, B lymphoid tyrosine kinase gene; ABCC8, ATP-binding cassette transporter sub-family C member 8 gene; KCNJ11, potassium voltage-gated channel subfamily J member 11 gene; APPL1, Adaptor Protein, Phosphotyrosine interacting with PH domain and Leucine zipper 1.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">MODY subtype \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Gene \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Relative prevalence \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Pathophysiology \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Clinical phenotype \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Frequency of microvascular complications \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Proper management \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">HNF-4α</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5–10% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">β-Cell dysfunction (mainly insulin secretory defect) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Transient neonatal hyperinsulinemia and hypoglycemia with associated macrossomia;Gestational diabetes;Progressive insulin secretory defect;Low serum levels of triglycerides, Apo AI, AII and CIII;Marked sensitivity to sulfonylureas \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Common \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sensitive to sulfonylureas \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">GCK</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">30–50% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">β-Cell dysfunction (glucose-sensing defect) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Stable, mild fasting hyperglycemia throughout life;Typically asymptomatic; diagnosis often incidental;Gestational diabetes;Variation in birth weight \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rare \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diet and exercise \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">HNF-1α</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">30–65% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">β-Cell dysfunction (mainly insulin secretory defect) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Transient neonatal hyperinsulinemia and hypoglycemia for some;OGTT frequently needed to make an early diagnosis;Diminished renal threshold for glycosuria;Progressive insulin secretory defect;Marked sensitivity to sulfonylureas, and fair results with nateglinide \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Common \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Low-dose to sulfonylureas or meglitinides; GLP-1 agonists also used;Insulin may be required \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">IPF 1</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><1% (rare) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">β-Cell dysfunction \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pancreatic agenesis (homozygosis form) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Unknown \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diet; OADs; insulin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">HNF-1β</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><5% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">β-Cell dysfunction \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Intrauterine growth restriction;Renal abnormalities and insufficiency at young age;Urogenital tract anomalies;Diabetes often diagnosed later;Liver test abnormalities;Pancreatic atrophy or partial agenesis, exocrine pancreatic dysfunction;Hyperuricemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Common \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">A minority response to sulfonylureas;Insulin is commonly required \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Neuro D1 or BETA2</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><1% (very rare) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">β-Cell dysfunction \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pancreatic anomalies \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Unknown \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diet; OADs; insulin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">KLF11</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><1% (very rare) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Decreased glucose sensitivity of β-cells \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pancreatic malignancy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Unknown \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">OADs; insulin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">CEL</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><1% (very rare) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pancreatic endocrine and exocrine dysfunction \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pancreatic atrophy and exocrine pancreatic insufficiency;Fibrosis and lipomatosis with posterior diabetes development \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Unknown \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">OADs; insulin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">PAX 4</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><1% (very rare) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">β-Cell dysfunction \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ketosis-prone diabetes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Unknown \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diet; OADs; insulin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">INS</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><1% (very rare) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">β-Cell dysfunction \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Neonatal diabetesPhenotype variability \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Unknown \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diet; OADs; insulin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">BLK</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><1% (very rare) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Insulin secretion defect \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Overweight/obesity for some \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Unknown \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diet; OADs; insulin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">ABCC8</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><1% (very rare) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ATP-sensitive potassium channel dysfunction \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Similar to <span class="elsevierStyleItalic">HNF-1α</span> and <span class="elsevierStyleItalic">HNF-4α</span> related MODY subtypes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Unknown \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sulfonylureas \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">KCNJ11</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><1% (very rare) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ATP-sensitive potassium channel dysfunction \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Similar to <span class="elsevierStyleItalic">HNF-1α</span> and <span class="elsevierStyleItalic">HNF-4α</span> related MODY subtypes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Unknown \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diet; sulfonylureas; insulin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">APPL1</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><1% (very rare) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Insulin secretion defect \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Dysmorphic phenotype and delay in the development \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Unknown \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diet; OADs; insulin \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2239256.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">The different MODY subtypes and their related molecular basis, clinical features and proper management.</p>" ] ] 3 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">T1DM, Type 1 Diabetes Mellitus; T2DM, Type 2 Diabetes Mellitus; <span class="elsevierStyleItalic">hs</span>-CRP, high sensitivity C-reactive protein.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Features \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">T1DM \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">T2DM \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">MODY \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Disease onset \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SuddenUsually<35 years old \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SlowUsually>35 years old \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SlowUsually<25 years old \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Family history of diabetes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Minor relevance \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Relevant \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Essential \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Etiology \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Polygenic<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> and immunologic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Polygenic and environmental factors<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Monogenic<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> with negligible environmental factors \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Insulin dependent \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diabetic ketoacidosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Common \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rare \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rare \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Obesity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Generally absent \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Common \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rare \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Insulin resistance \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rare \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Common \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rare \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Beta-cell antibodies \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">>90% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Negative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rare \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">C-peptide levels \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Low/undetectable \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Normal/high \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Normal \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">hs-CRP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Normal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mild chronic elevation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Normal/low \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Micro/macrovascular complications \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">From rare to common \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">First-line treatment \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Insulin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Metformin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DietSulfonylureas/meglitinide/other OADsInsulin may be required \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2239255.png" ] ] ] "notaPie" => array:3 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Polygenic genetic predisposition: several genes with mutation causes diabetes.</p>" ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Environmental factors: obesity, sedentary lifestyle and unbalanced diet.</p>" ] 2 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "c" "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Monogenic genetic predisposition: one mutated gene causes diabetes.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Differential diagnosis of distinctive forms of diabetes.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:69 [ 0 => array:3 [ "identificador" => "bib0350" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes – 2019" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "American Diabetes Association" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/dc19-S002" "Revista" => array:7 [ "tituloSerie" => "Diabetes Care" "fecha" => "2019" "volumen" => "42" "numero" => "Suppl. 1" "paginaInicial" => "S13" "paginaFinal" => "S28" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30559228" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0355" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hidden MODY – looking for a needle in a haystack" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J. Urbanová" 1 => "L. Brunerová" 2 => "J. Brož" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Front Endocrinol" "fecha" => "2018" "volumen" => "9" "paginaInicial" => "355" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0360" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Not quite type 1 or type 2, what now? Review of monogenic, mitochondrial, and syndromic diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "R. Yeung" 1 => "F. Hannah-Shmouni" 2 => "K. Niederhoffer" 3 => "M.A. Walker" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11154-018-9446-3" "Revista" => array:6 [ "tituloSerie" => "Rev. Endocr. Metab. Disord." "fecha" => "2018" "volumen" => "19" "paginaInicial" => "35" "paginaFinal" => "52" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29777474" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0365" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genetic testing of maturity-onset diabetes of the young current status and future perspectives" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Firdous" 1 => "K. Nissar" 2 => "S. Ali" 3 => "B.A. Ganai" 4 => "U. Shabir" 5 => "T. Hassan" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Front Endocrinol" "fecha" => "2018" "volumen" => "9" "paginaInicial" => "1" "paginaFinal" => "13" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0370" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Maturity onset diabetes of the young: seek and you will find" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "H. Heuvel-Borsboom" 1 => "H.W. de Valk" 2 => "M. Losekoot" 3 => "J. Westerink" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Neth. J. Med." "fecha" => "2016" "volumen" => "74" "paginaInicial" => "193" "paginaFinal" => "200" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27323672" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0375" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "MODY: history, genetics, pathophysiology, and clinical decision making" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S.S. Fajans" 1 => "G.I. Bell" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/dc11-0035" "Revista" => array:6 [ "tituloSerie" => "Diabetes Care" "fecha" => "2011" "volumen" => "34" "paginaInicial" => "1878" "paginaFinal" => "1884" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21788644" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0380" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Maturity-onset diabetes of the young: what do clinicians need to know?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "S.H. Kim" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4093/dmj.2015.39.6.468" "Revista" => array:6 [ "tituloSerie" => "Diabetes Metab J" "fecha" => "2015" "volumen" => "39" "paginaInicial" => "468" "paginaFinal" => "477" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26706916" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0385" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Maturity-onset diabetes of the young overview. GeneReviews® [Internet]" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R. Naylor" 1 => "A.K. Johnson" 2 => "D. del Gaudio" ] ] ] ] ] "host" => array:2 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2018" ] ] 1 => array:1 [ "WWW" => array:1 [ "link" => "http://www.ncbi.nlm.nih.gov/books/NBK500456/" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0390" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The maturity-onset diabetes of the young (MODY1) transcription factor HNF-4α regulates expression of genes required for glucose transport and metabolism" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M. Stoffel" 1 => "S.A. Duncan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1073/pnas.94.24.13209" "Revista" => array:6 [ "tituloSerie" => "Proc. Natl. Acad. Sci. U.S.A." "fecha" => "1997" "volumen" => "94" "paginaInicial" => "13209" "paginaFinal" => "13214" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9371825" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0395" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY 3)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Yamagata" 1 => "N. Oda" 2 => "P.J. Kaisaki" 3 => "S. Menzel" 4 => "H. Furuta" 5 => "M. Vaxillaire" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/384455a0" "Revista" => array:6 [ "tituloSerie" => "Nature" "fecha" => "1996" "volumen" => "384" "paginaInicial" => "455" "paginaFinal" => "458" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8945470" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0400" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY 1)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Yamagata" 1 => "H. Furuta" 2 => "N. Oda" 3 => "P.J. Kaisaki" 4 => "S. Menzel" 5 => "N.J. Cox" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/384458a0" "Revista" => array:6 [ "tituloSerie" => "Nature" "fecha" => "1996" "volumen" => "384" "paginaInicial" => "458" "paginaFinal" => "460" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8945471" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0405" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Maturity-onset diabetes of the young (MODY): making the right diagnosis to optimize treatment" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S. Amed" 1 => "R. Oram" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jcjd.2016.03.002" "Revista" => array:6 [ "tituloSerie" => "Can J Diabetes" "fecha" => "2016" "volumen" => "40" "paginaInicial" => "449" "paginaFinal" => "454" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27130141" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0410" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatocyte nuclear factor 4α regulates the expression of pancreatic β-cell genes implicated in glucose metabolism and nutrient-induced insulin secretion" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "H. Wang" 1 => "P. Maechler" 2 => "P.A. Antinozzi" 3 => "K.A. Hagenfeldt" 4 => "C.B. Wollheim" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1074/jbc.M006612200" "Revista" => array:6 [ "tituloSerie" => "J. Biol. Chem." "fecha" => "2000" "volumen" => "275" "paginaInicial" => "35953" "paginaFinal" => "35959" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10967120" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0415" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical features and treatment of maturity-onset diabetes of the young (MODY)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "D. Gardner" 1 => "S. Tai" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2147/DMSO.S23353" "Revista" => array:6 [ "tituloSerie" => "Diabetes Metab Syndr Obes" "fecha" => "2012" "volumen" => "5" "paginaInicial" => "101" "paginaFinal" => "108" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22654519" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0420" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Administration of sulfonylureas can increase glucose-induced insulin secretion for decades in patients with maturity-onset diabetes of the young" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S.S. Fajans" 1 => "M.B. Brown" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/diacare.16.9.1254" "Revista" => array:6 [ "tituloSerie" => "Diabetes Care" "fecha" => "1993" "volumen" => "16" "paginaInicial" => "1254" "paginaFinal" => "1261" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8404429" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0425" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Maturity-onset diabetes of the young (MODY): an update" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A. Anik" 1 => "G. Çatli" 2 => "A. Abaci" 3 => "E. Böber" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Pediatr Endocr Met" "fecha" => "2015" "volumen" => "28" "paginaInicial" => "251" "paginaFinal" => "263" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0430" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Stride" 1 => "S. Ellard" 2 => "P. Clark" 3 => "L. Shakespeare" 4 => "M. Salzmann" 5 => "M. Shepherd" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/diacare.28.7.1751" "Revista" => array:6 [ "tituloSerie" => "Diabetes Care" "fecha" => "2005" "volumen" => "28" "paginaInicial" => "1751" "paginaFinal" => "1756" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15983330" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0435" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S.S. Fajans" 1 => "G.I. Bell" 2 => "S.K. Polonsky" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMra002168" "Revista" => array:6 [ "tituloSerie" => "N. Engl. J. Med." "fecha" => "2001" "volumen" => "345" "paginaInicial" => "971" "paginaFinal" => "980" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11575290" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0440" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "HNF1α controls renal glucose reabsorption in mouse and man" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Pontoglio" 1 => "D. Prié" 2 => "C. Cheret" 3 => "A. Doyen" 4 => "C. Leroy" 5 => "P. Froguel" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "EMBO Rep." "fecha" => "2000" "volumen" => "4" "paginaInicial" => "359" "paginaFinal" => "365" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0445" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genotype/phenotype relationships in HNF-4α/MODY1: haploinsufficiency is associated with reduced apolipoprotein (AII), apolipoprotein (CIII), lipoprotein(a), and triglyceride levels" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "D.Q. Shih" 1 => "H.M. Dansky" 2 => "M. Fleisher" 3 => "G. Assmann" 4 => "S.S. Fajans" 5 => "M. Stoffel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/diabetes.49.5.832" "Revista" => array:6 [ "tituloSerie" => "Diabetes" "fecha" => "2000" "volumen" => "49" "paginaInicial" => "832" "paginaFinal" => "837" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10905494" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0450" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genetic cause of hyperglycaemia and response to treatment in diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "E.R. Pearson" 1 => "B.J. Starkey" 2 => "R.J. Powell" 3 => "F.M. Gribble" 4 => "P.M. Clark" 5 => "A.T. Hattersley" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(03)14571-0" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2003" "volumen" => "362" "paginaInicial" => "1275" "paginaFinal" => "1281" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14575972" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0455" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "T. Tuomi" 1 => "E.H. Honkanen" 2 => "B. Isomaa" 3 => "L. Sarelin" 4 => "L.C. Groop" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/diacare.29.02.06.dc05-1314" "Revista" => array:6 [ "tituloSerie" => "Diabetes Care" "fecha" => "2006" "volumen" => "29" "paginaInicial" => "189" "paginaFinal" => "194" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16443858" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0460" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Osbak" 1 => "K. Colclough" 2 => "C. Saint-Martin" 3 => "N.L. Beer" 4 => "C. Bellanné-Chantelot" 5 => "S. Ellard" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/humu.21110" "Revista" => array:6 [ "tituloSerie" => "Hum. Mutat." "fecha" => "2009" "volumen" => "30" "paginaInicial" => "1512" "paginaFinal" => "1526" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19790256" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0465" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Maturity onset diabetes of the young: clinical characteristics, diagnosis and management" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "F.K. Kavvoura" 1 => "K.R. Owen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Pediatr Endocrinol Rev" "fecha" => "2012" "volumen" => "10" "paginaInicial" => "234" "paginaFinal" => "242" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23539835" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0470" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mutations in hepatocyte nuclear factor-1b and their related phenotypes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "E.L. Edghill" 1 => "C. Bingham" 2 => "S. Ellard" 3 => "A.T. Hattersley" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/jmg.2005.032854" "Revista" => array:6 [ "tituloSerie" => "J. Med. Genet." "fecha" => "2006" "volumen" => "43" "paginaInicial" => "84" "paginaFinal" => "90" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15930087" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0475" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mutation in hepatocyte nuclear factor-1b gene (TCF2) associated with MODY" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y. Horikawa" 1 => "N. Iwasaki" 2 => "M. Hara" 3 => "H. Furuta" 4 => "Y. Hinokio" 5 => "B.N. Cockburn" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/ng1297-384" "Revista" => array:6 [ "tituloSerie" => "Nat. Genet." "fecha" => "1997" "volumen" => "17" "paginaInicial" => "384" "paginaFinal" => "385" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9398836" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0480" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Severe pancreas hypoplasia and multicystic renal dysplasia in two human fetuses carrying novel HNF1/MODY5 mutations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "C. Haumaitre" 1 => "M. Fabre" 2 => "S. Cormier" 3 => "C. Baumann" 4 => "A.L. Delezoide" 5 => "S. Cereghini" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/hmg/ddl161" "Revista" => array:6 [ "tituloSerie" => "Hum. Mol. Genet." "fecha" => "2006" "volumen" => "15" "paginaInicial" => "2363" "paginaFinal" => "2375" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16801329" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0485" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Contrasting diabetes phenotypes associated with hepatocyte nuclear factor-1α and -1β mutations" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.R. Pearson" 1 => "M.K. Badman" 2 => "C.R. Lockwood" 3 => "P.M. Clark" 4 => "S. Ellard" 5 => "C. Bingham" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/diacare.27.5.1102" "Revista" => array:6 [ "tituloSerie" => "Diabetes Care" "fecha" => "2004" "volumen" => "27" "paginaInicial" => "1102" "paginaFinal" => "1107" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15111528" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0490" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early-onset type-II diabetes mellitus (MODY4) linked to IPF1" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "D.A. Stoffers" 1 => "J. Ferrer" 2 => "W.L. Clarke" 3 => "S. Menzel" 4 => "H. Furuta" 5 => "M. Vaxillaire" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/ng1097-138" "Revista" => array:6 [ "tituloSerie" => "Nat. Genet." "fecha" => "1997" "volumen" => "17" "paginaInicial" => "138" "paginaFinal" => "139" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9326926" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0495" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impaired insulin secretion and increased insulin sensitivity in familial maturity-onset diabetes of the young 4 (insulin promoter factor 1 gene)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.R. Clocquet" 1 => "J.M. Egan" 2 => "D.A. Stoffers" 3 => "D.C. Muller" 4 => "L. Wideman" 5 => "G.A. Chin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/diabetes.49.11.1856" "Revista" => array:6 [ "tituloSerie" => "Diabetes" "fecha" => "2000" "volumen" => "49" "paginaInicial" => "1856" "paginaFinal" => "1864" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11078452" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0500" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "IPF-1/MODY4 gene missense mutation in an Italian family with type 2 and gestational diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "C. Gragnoli" 1 => "V. Stanojevic" 2 => "A. Gorini" 3 => "P.J. Kaisaki" 4 => "S. Menzel" 5 => "N.J. Cox" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.metabol.2005.01.037" "Revista" => array:6 [ "tituloSerie" => "Metabolism." "fecha" => "2005" "volumen" => "54" "paginaInicial" => "983" "paginaFinal" => "988" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16092045" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0505" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An infant with combination gene mutations for Monogenic Diabetes of Youth (MODY) 2 and 4, presenting with Diabetes Mellitus Requiring Insulin (DMRI) at 8 months of age" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Odem" 1 => "E. Munzinger" 2 => "S. Violand" 3 => "A. Van Morlan" 4 => "D. Rife" 5 => "B. Bachrach" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1399-5448.2009.00515.x" "Revista" => array:6 [ "tituloSerie" => "Pediatr Diabetes" "fecha" => "2009" "volumen" => "10" "paginaInicial" => "550" "paginaFinal" => "553" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19515026" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0510" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Obesity and hyperinsulinemia in a family with pancreatic agenesis and MODY due to the IPF1 mutation Pro63fsX60" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.S. Fajans" 1 => "G.I. Bell" 2 => "V.P. Paz" 3 => "J.E. Below" 4 => "N.J. Cox" 5 => "C. Martin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.trsl.2010.03.003" "Revista" => array:6 [ "tituloSerie" => "Transl Res" "fecha" => "2010" "volumen" => "156" "paginaInicial" => "7" "paginaFinal" => "14" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20621032" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0515" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.T. Malecki" 1 => "U.S. Jhala" 2 => "A. Antonellis" 3 => "L. Fields" 4 => "A. Doria" 5 => "T. Orban" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/15500" "Revista" => array:6 [ "tituloSerie" => "Nat. Genet." "fecha" => "1999" "volumen" => "23" "paginaInicial" => "323" "paginaFinal" => "328" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10545951" "web" => "Medline" ] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0520" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "NEUROD1-deficient diabetes (MODY6): identification of the first cases in Japanese and the clinical features" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y. Horikawa" 1 => "M. Enya" 2 => "H. Mabe" 3 => "K. Fukushima" 4 => "N. Takubo" 5 => "M. Ohashi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/pedi.12553" "Revista" => array:6 [ "tituloSerie" => "Pediatr Diabetes" "fecha" => "2018" "volumen" => "19" "paginaInicial" => "236" "paginaFinal" => "242" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28664602" "web" => "Medline" ] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0525" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Homozygous mutations in NeuroD1 are responsible for a novel syndrome of permanent neonatal diabetes and neurological abnormalities" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "O. Rubio-Cabezas" 1 => "J.A. Minton" 2 => "I. Kantor" 3 => "D. Williams" 4 => "S. Ellard" 5 => "A.T. Hattersley" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/db10-0011" "Revista" => array:6 [ "tituloSerie" => "Diabetes" "fecha" => "2010" "volumen" => "59" "paginaInicial" => "2326" "paginaFinal" => "2331" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20573748" "web" => "Medline" ] ] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0530" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic beta cell function" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B. Neve" 1 => "M.E. Fernandez-Zapico" 2 => "V. Ashkenazi-Katalan" 3 => "C. Dina" 4 => "Y.H. Hamid" 5 => "E. Joly" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1073/pnas.0409177102" "Revista" => array:6 [ "tituloSerie" => "Proc. Natl. Acad. Sci. U.S.A." "fecha" => "2005" "volumen" => "102" "paginaInicial" => "4807" "paginaFinal" => "4812" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15774581" "web" => "Medline" ] ] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0535" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "MODY7 gene, KLF11, is a novel p300-dependent regulator of Pdx-1 (MODY4) transcription in pancreatic islet beta cells" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.E. Fernandez-Zapico" 1 => "J.C. Van Velkinburgh" 2 => "R. Gutierrez-Aguilar" 3 => "B. Neve" 4 => "P. Froguel" 5 => "R. Urrutia" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1074/jbc.M109.028852" "Revista" => array:6 [ "tituloSerie" => "J. Biol. Chem." "fecha" => "2009" "volumen" => "284" "paginaInicial" => "36482" "paginaFinal" => "36490" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19843526" "web" => "Medline" ] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0540" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl ester lipase gene-maturity onset diabetes of the young (CEL-MODY): a protein misfolding disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B.B. Johansson" 1 => "J. Torsvik" 2 => "L. Bjørkhaug" 3 => "M. Vesterhus" 4 => "A. Ragvin" 5 => "E. Tjora" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J. Biol. Chem." "fecha" => "2011" "volumen" => "286" "paginaInicial" => "593" "paginaFinal" => "605" ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0545" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pancreatic adenocarcinoma, chronic pancreatitis, and MODY-8 diabetes: is bile salt-dependent lipase (or carboxyl ester lipase) at the crossroads of pancreatic pathologies?" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Lombardo" 1 => "F. Silvy" 2 => "I. Crenon" 3 => "E. Martinez" 4 => "A. Collignon" 5 => "E. Beraud" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.18632/oncotarget.23619" "Revista" => array:6 [ "tituloSerie" => "Oncotarget" "fecha" => "2018" "volumen" => "9" "paginaInicial" => "12513" "paginaFinal" => "12533" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29552330" "web" => "Medline" ] ] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0550" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H. Raeder" 1 => "S. Johansson" 2 => "P.I. Holm" 3 => "I.S. Haldorsen" 4 => "E. Mas" 5 => "V. Sbarra" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/ng1708" "Revista" => array:6 [ "tituloSerie" => "Nat. Genet." "fecha" => "2006" "volumen" => "38" "paginaInicial" => "54" "paginaFinal" => "62" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16369531" "web" => "Medline" ] ] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0555" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Branched fatty acid esters of hydroxy fatty acids are preferred substrates of the MODY8 protein carboxyl ester lipase" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.J. Kolar" 1 => "S.S. Kamat" 2 => "W.H. Parsons" 3 => "E.A. Homan" 4 => "T. Maher" 5 => "O.D. Peroni" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1021/acs.biochem.6b00565" "Revista" => array:6 [ "tituloSerie" => "Biochemistry" "fecha" => "2016" "volumen" => "55" "paginaInicial" => "4636" "paginaFinal" => "4641" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27509211" "web" => "Medline" ] ] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0560" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The Pax4 gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "B. Sosa-Pineda" 1 => "K. Chowdhury" 2 => "M. Torres" 3 => "G. Oliver" 4 => "P. Gruss" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/386399a0" "Revista" => array:6 [ "tituloSerie" => "Nature" "fecha" => "1997" "volumen" => "386" "paginaInicial" => "399" "paginaFinal" => "402" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9121556" "web" => "Medline" ] ] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0565" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PAX4 mutations in Thais with maturity onset diabetes of the young" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Plengvidhya" 1 => "S. Kooptiwut" 2 => "N. Songtawee" 3 => "A. Doi" 4 => "H. Furuta" 5 => "M. Nishi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1210/jc.2006-1927" "Revista" => array:6 [ "tituloSerie" => "J. Clin. Endocrinol. Metab." "fecha" => "2007" "volumen" => "92" "paginaInicial" => "2821" "paginaFinal" => "2826" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17426099" "web" => "Medline" ] ] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0570" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Aberrant mRNA splicing of paired box 4 (PAX4) IVS7-1G>A mutation causing maturity-onset diabetes of the young, type 9" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Sujjitjoon" 1 => "S. Kooptiwut" 2 => "N. Chongjaroen" 3 => "W. Tangjittipokin" 4 => "N. Plengvidhya" 5 => "P.T. Yenchitsomanus" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00592-015-0760-x" "Revista" => array:6 [ "tituloSerie" => "Acta Diabetol." "fecha" => "2016" "volumen" => "53" "paginaInicial" => "205" "paginaFinal" => "216" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25951767" "web" => "Medline" ] ] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0575" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PAX4 gene variations predispose to ketosis-prone diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "F. Mauvais-Jarvis" 1 => "S.B. Smith" 2 => "C. Le May" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/hmg/ddh341" "Revista" => array:6 [ "tituloSerie" => "Hum. Mol. Genet." "fecha" => "2004" "volumen" => "13" "paginaInicial" => "3151" "paginaFinal" => "3159" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15509590" "web" => "Medline" ] ] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0580" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Insulin gene mutations resulting in early-onset diabetes: marked differences in clinical presentation, metabolic status, and pathogenic effect through endoplasmic reticulum retention" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Meur" 1 => "A. Simon" 2 => "N. Harun" 3 => "M. Virally" 4 => "A. Dechaume" 5 => "A. Bonnefond" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/db09-1091" "Revista" => array:6 [ "tituloSerie" => "Diabetes" "fecha" => "2010" "volumen" => "59" "paginaInicial" => "653" "paginaFinal" => "661" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20007936" "web" => "Medline" ] ] ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0585" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.L. Edghill" 1 => "S.E. Flanagan" 2 => "A.M. Patch" 3 => "C. Boustred" 4 => "A. Parrish" 5 => "B. Shields" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/db07-1405" "Revista" => array:6 [ "tituloSerie" => "Diabetes" "fecha" => "2008" "volumen" => "57" "paginaInicial" => "1034" "paginaFinal" => "1042" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18162506" "web" => "Medline" ] ] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0590" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Further evidence that mutations in INS can be a rare cause of maturity-onset diabetes of the young (MODY)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T.W. Boesgaard" 1 => "S. Pruhova" 2 => "E.A. Andersson" 3 => "O. Cinek" 4 => "B. Obermannova" 5 => "J. Lauenborg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2350-11-42" "Revista" => array:5 [ "tituloSerie" => "BMC Med Genet" "fecha" => "2010" "volumen" => "11" "paginaInicial" => "42" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20226046" "web" => "Medline" ] ] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0595" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mutations at the BLK locus linked to maturity onset diabetes of the young and β-cell dysfunction" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M.E. Borowiec" 1 => "W. Chong" 2 => "R. Thompson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1073/pnas.0906474106" "Revista" => array:6 [ "tituloSerie" => "Proc. Natl. Acad. Sci. U.S.A." "fecha" => "2009" "volumen" => "106" "paginaInicial" => "14460" "paginaFinal" => "14465" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19667185" "web" => "Medline" ] ] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0600" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Identification of a locus for maturity-onset diabetes of the young on chromosome 8p23" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.H. Kim" 1 => "X. Ma" 2 => "S. Weremowicz" 3 => "T. Ercolino" 4 => "C. Powers" 5 => "W. Mlynarski" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/diabetes.53.5.1375" "Revista" => array:6 [ "tituloSerie" => "Diabetes" "fecha" => "2004" "volumen" => "53" "paginaInicial" => "1375" "paginaFinal" => "1384" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15111509" "web" => "Medline" ] ] ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0605" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Heterozygous ABCC8 mutations are a cause of MODY" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Bowman" 1 => "S.E. Flanagan" 2 => "E.L. Edghill" 3 => "A. Damhuis" 4 => "M.H. Shepherd" 5 => "R. Paisey" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00125-011-2319-x" "Revista" => array:6 [ "tituloSerie" => "Diabetologia" "fecha" => "2012" "volumen" => "55" "paginaInicial" => "123" "paginaFinal" => "127" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21989597" "web" => "Medline" ] ] ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0610" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A rare mutation in ABCC8/SUR1 leading to altered ATP-sensitive K<span class="elsevierStyleSup">+</span> channel activity and beta-cell glucose sensing is associated with type 2 diabetes in adults" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.I. Tarasov" 1 => "T.J. Nicolson" 2 => "J.P. Riveline" 3 => "T.K. Taneja" 4 => "S.A. Baldwin" 5 => "J.M. Baldwin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/db07-1547" "Revista" => array:6 [ "tituloSerie" => "Diabetes" "fecha" => "2008" "volumen" => "57" "paginaInicial" => "1595" "paginaFinal" => "1604" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18346985" "web" => "Medline" ] ] ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0615" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Whole-exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Bonnefond" 1 => "J. Philippe" 2 => "E. Durand" 3 => "A. Dechaume" 4 => "M. Huyvaert" 5 => "L. Montagne" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0037423" "Revista" => array:5 [ "tituloSerie" => "PLoS One" "fecha" => "2012" "volumen" => "7" "paginaInicial" => "e37423" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22701567" "web" => "Medline" ] ] ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0620" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Loss-of-function mutations in APPL1 in familial diabetes mellitus" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Prudente" 1 => "P. Jungtrakoon" 2 => "A. Marucci" 3 => "O. Ludovico" 4 => "P. Buranasupkajorn" 5 => "T. Mazza" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ajhg.2015.05.011" "Revista" => array:6 [ "tituloSerie" => "Am. J. Hum. Genet." "fecha" => "2015" "volumen" => "97" "paginaInicial" => "177" "paginaFinal" => "185" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26073777" "web" => "Medline" ] ] ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0625" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The endosomal protein Appl1 mediates Akt substrate specificity and cell survival in vertebrate development" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Schenck" 1 => "L. Goto-Silva" 2 => "C. Collinet" 3 => "M. Rhinn" 4 => "A. Giner" 5 => "B. Habermann" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cell.2008.02.044" "Revista" => array:6 [ "tituloSerie" => "Cell" "fecha" => "2008" "volumen" => "133" "paginaInicial" => "486" "paginaFinal" => "497" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18455989" "web" => "Medline" ] ] ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0630" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lessons from whole-exome sequencing in MODYX families" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Dusatkova" 1 => "M. Fang" 2 => "S. Pruhova" 3 => "A.P. Gjesing" 4 => "O. Cinek" 5 => "T. Hansen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Diabetes Res. Clin. Pract." "fecha" => "2014" "volumen" => "104" "paginaInicial" => "72" "paginaFinal" => "74" ] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib0635" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A genome-wide scan in families with maturity-onset diabetes of the young: evidence for further genetic heterogeneity" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T.M. Frayling" 1 => "C.M. Lindgren" 2 => "J.C. Chevre" 3 => "S. Menzel" 4 => "M. Wishart" 5 => "Y. Benmezroua" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/diabetes.52.3.872" "Revista" => array:6 [ "tituloSerie" => "Diabetes" "fecha" => "2003" "volumen" => "52" "paginaInicial" => "872" "paginaFinal" => "881" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12606533" "web" => "Medline" ] ] ] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib0640" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genetics of monogenic diabetes: present clinical challenges" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S. Misra" 1 => "K.R. Owen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11892-018-0969-5" "Revista" => array:6 [ "tituloSerie" => "Curr Diab Rep" "fecha" => "2018" "volumen" => "18" "paginaInicial" => "1" "paginaFinal" => "11" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29362940" "web" => "Medline" ] ] ] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib0645" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnosis and management of maturity onset diabetes of the young (MODY)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "G. Thanabalasingham" 1 => "K.R. Owen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/bmj.d6044" "Revista" => array:5 [ "tituloSerie" => "BMJ" "fecha" => "2011" "volumen" => "343" "paginaInicial" => "d6044" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22012810" "web" => "Medline" ] ] ] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib0650" "etiqueta" => "61" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genetic testing for monogenic diabetes using targeted next-generation sequencing in patients with maturity-onset diabetes of the young" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Szopa" 1 => "A. Ludwig-Gałęzowska" 2 => "P. Radkowski" 3 => "J. Skupień" 4 => "B. Zapała" 5 => "T. Płatek" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.20452/pamw.3164" "Revista" => array:6 [ "tituloSerie" => "Pol. Arch. Med. Wewn." "fecha" => "2015" "volumen" => "125" "paginaInicial" => "845" "paginaFinal" => "851" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26552609" "web" => "Medline" ] ] ] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib0655" "etiqueta" => "62" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Molecular diagnosis of maturity onset diabetes of the young in India" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "V. Nair" 1 => "A. Chapla" 2 => "N. Arulappan" 3 => "N. Thomas" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Indian J Endocrinol Metab" "fecha" => "2013" "volumen" => "17" "paginaInicial" => "430" "paginaFinal" => "441" ] ] ] ] ] ] 62 => array:3 [ "identificador" => "bib0660" "etiqueta" => "63" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M. Vaxillaire" 1 => "P. Froguel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1210/er.2007-0024" "Revista" => array:6 [ "tituloSerie" => "Endocr. Rev." "fecha" => "2008" "volumen" => "29" "paginaInicial" => "254" "paginaFinal" => "264" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18436708" "web" => "Medline" ] ] ] ] ] ] ] ] 63 => array:3 [ "identificador" => "bib0665" "etiqueta" => "64" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "B.M. Shields" 1 => "T.J. McDonald" 2 => "S. Ellard" 3 => "M.J. Campbell" 4 => "C. Hyde" 5 => "A.T. Hattersley" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Diabetologia" "fecha" => "2012" "volumen" => "55" "paginaInicial" => "1265" "paginaFinal" => "1272" ] ] ] ] ] ] 64 => array:3 [ "identificador" => "bib0670" "etiqueta" => "65" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Population-based assessment of a biomarker-based screening pathway to aid diagnosis of monogenic diabetes in young-onset patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B.M. Shields" 1 => "M. Shepherd" 2 => "M. Hudson" 3 => "T.J. McDonald" 4 => "K. Colclough" 5 => "J. Peters" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/dc17-0224" "Revista" => array:6 [ "tituloSerie" => "Diabetes Care" "fecha" => "2017" "volumen" => "40" "paginaInicial" => "1017" "paginaFinal" => "1025" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28701371" "web" => "Medline" ] ] ] ] ] ] ] ] 65 => array:3 [ "identificador" => "bib0675" "etiqueta" => "66" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.E. Besser" 1 => "M.H. Shepherd" 2 => "T.J. McDonald" 3 => "B.M. Shields" …2 ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/dc10-1293" "Revista" => array:6 [ "tituloSerie" => "Diabetes Care" "fecha" => "2011" "volumen" => "34" "paginaInicial" => "286" "paginaFinal" => "291" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 66 => array:3 [ "identificador" => "bib0680" "etiqueta" => "67" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/dc11-0323" "Revista" => array:6 [ "tituloSerie" => "Diabetes Care" "fecha" => "2011" "volumen" => "34" "paginaInicial" => "1860" "paginaFinal" => "1862" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 67 => array:3 [ "identificador" => "bib0685" "etiqueta" => "68" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/dc10-0288" "Revista" => array:6 [ "tituloSerie" => "Diabetes Care" "fecha" => "2010" "volumen" => "33" "paginaInicial" => "1919" "paginaFinal" => "1924" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 68 => array:3 [ "identificador" => "bib0690" "etiqueta" => "69" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1464-5491.2011.03287.x" "Revista" => array:6 [ "tituloSerie" => "Diabet. Med." "fecha" => "2011" "volumen" => "28" "paginaInicial" => "1028" "paginaFinal" => "1033" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/25300164/0000006700000002/v1_202002131357/S2530016419302071/v1_202002131357/en/main.assets" "Apartado" => array:4 [ "identificador" => "64481" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Revisión" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/25300164/0000006700000002/v1_202002131357/S2530016419302071/v1_202002131357/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016419302071?idApp=UINPBA00004N" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 7 | 4 | 11 |
2024 October | 83 | 26 | 109 |
2024 September | 85 | 37 | 122 |
2024 August | 70 | 33 | 103 |
2024 July | 66 | 14 | 80 |
2024 June | 70 | 25 | 95 |
2024 May | 72 | 30 | 102 |
2024 April | 126 | 37 | 163 |
2024 March | 88 | 22 | 110 |
2024 February | 95 | 21 | 116 |
2024 January | 96 | 15 | 111 |
2023 December | 109 | 4 | 113 |
2023 November | 110 | 18 | 128 |
2023 October | 131 | 9 | 140 |
2023 September | 80 | 2 | 82 |
2023 August | 113 | 13 | 126 |
2023 July | 108 | 10 | 118 |
2023 June | 84 | 27 | 111 |
2023 May | 142 | 22 | 164 |
2023 April | 140 | 26 | 166 |
2023 March | 135 | 19 | 154 |
2023 February | 86 | 8 | 94 |
2023 January | 113 | 9 | 122 |
2022 December | 96 | 15 | 111 |
2022 November | 131 | 24 | 155 |
2022 October | 80 | 19 | 99 |
2022 September | 74 | 28 | 102 |
2022 August | 74 | 21 | 95 |
2022 July | 64 | 26 | 90 |
2022 June | 65 | 13 | 78 |
2022 May | 62 | 21 | 83 |
2022 April | 85 | 20 | 105 |
2022 March | 97 | 17 | 114 |
2022 February | 89 | 17 | 106 |
2022 January | 87 | 9 | 96 |
2021 December | 66 | 16 | 82 |
2021 November | 87 | 12 | 99 |
2021 October | 98 | 38 | 136 |
2021 September | 87 | 18 | 105 |
2021 August | 91 | 23 | 114 |
2021 July | 42 | 25 | 67 |
2021 June | 35 | 11 | 46 |
2021 May | 70 | 20 | 90 |
2021 April | 171 | 92 | 263 |
2021 March | 128 | 27 | 155 |
2021 February | 110 | 21 | 131 |
2021 January | 103 | 32 | 135 |
2020 December | 69 | 37 | 106 |
2020 November | 81 | 35 | 116 |
2020 October | 60 | 25 | 85 |
2020 September | 74 | 26 | 100 |
2020 August | 75 | 22 | 97 |
2020 July | 72 | 3 | 75 |
2020 June | 4 | 0 | 4 |
2020 May | 6 | 0 | 6 |
2020 April | 6 | 4 | 10 |
2020 March | 15 | 15 | 30 |
2020 February | 117 | 85 | 202 |
2019 December | 0 | 4 | 4 |
2019 November | 0 | 18 | 18 |